ArticleThe Journal of clinical investigation2025
A vaccine against cytomegalovirus: how close are we?
Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Immunofitness in the elderly: The role of vaccination in promoting healthy aging.Human vaccines & immunotherapeutics · 2026Review
- Cytomegalovirus Vaccines in Transplantation: History, Hurdles, and Hope.Transplant infectious disease : an official journal of the Transplantation Society · 2026Review
- Human Cytomegalovirus Genetic Diversity, Clinical Relevance, and Emerging Insights.Reviews in medical virology · 2026Review
- Organ-specific differences in the epidemiology of cytomegalovirus infections in high-risk (cytomegalovirus donor seropositive, recipient seronegative) solid organ transplant recipients with prolonged follow-up: A 10-year experience.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Human cytomegalovirus at the maternal-fetal interface: an overview of pathogenesis, defence, and interventions.Clinical science (London, England : 1979) · 2026Review
- Latent cytomegalovirus disrupts innate NK cell responses to P. falciparum and impairs parasite control in first infection in adults.PLoS pathogens · 2026Article
- Article
- Congenital CMV and Hearing Loss-How Does it Happen and How to Prevent it.Reviews in medical virology · 2026Review
- Why do we have a vaccine for measles, but not cytomegalovirus (CMV)?PLoS pathogens · 2026Article
- Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR-T Cell Recipients-PART 2: Antiviral Therapy and Virus-Specific T Cell Therapy for HCMV in Allo-HSCT.Reviews in medical virology · 2026Review
- The Management of Congenital Cytomegalovirus Infection in an Era of Universal Newborn CMV Screening.Reviews in medical virology · 2026Review
- Cytomegalovirus in HIV: A Modifiable Driver of Inflammation, Frailty, and Aging.Current HIV/AIDS reports · 2026Review
- Recent insights into the immunobiology of congenital cytomegalovirus infection.Current opinion in physiology · 2026Article
- Cytomegalovirus-encoded immediate early 1 protein perturbs neural progenitor proliferation via interfering with host PML-DISC1 interaction.The Journal of biological chemistry · 2026Article
- Recent Trends in Cytomegalovirus IgG Seropositivity in the Adult Population of Korea: a Cross-Sectional Study and Literature Review.Annals of laboratory medicine · 2026Review
- Vaccination Against Pathogens Targeting Cell-Derived Cryptic Antigens.The Journal of infectious diseases · 2026Article
- Fetal and Neonatal Immune Response to Congenital Cytomegalovirus (cCMV) Infection: A Systematically Conducted Scoping Review.Viruses · 2026Article
- MAPKAP Kinase 2 Orchestrates Memory T Cell Inflation in Cytomegalovirus Infection.bioRxiv : the preprint server for biology · 2026Article
- Innovation in active and passive immunisation of people who are immunocompromised: a call to action.The Lancet. Infectious diseases · 2026Review
- Quarantine-associated viral pathogens in non-human primates: pathobiology, diagnostic surveillance, control strategies, and one health implications.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The pursuit of a vaccine against the human cytomegalovirus (HCMV) has been ongoing for more than 50 years. HCMV is the leading infectious cause of birth defects, including damage to the brain, and is a common cause of complications in organ transplantation. The complex biology of HCMV has made vaccine development difficult, but a recent meeting sponsored by the National Institute of Allergy and Infectious Diseases in September of 2023 brought together experts from academia, industry, and federal agencies to discuss progress in the field. The meeting reviewed the status of candidate HCMV vaccines under study and the challenges in clinical trial design in demonstrating efficacy against congenital CMV infection or the reduction of HCMV disease following solid organ transplantation or hematopoietic stem cell transplantation. Discussion in the meeting revealed that, with the numerous candidate vaccines that are under study, it is clear that a safe and effective HCMV vaccine is within reach. Meeting attendees achieved a consensus opinion that even a partially effective vaccine would have a major effect on the global health consequences of HCMV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.